A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 10 mg Once-daily in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Vonoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda
- 27 Dec 2016 Planned End Date changed from 31 May 2018 to 1 Jun 2018.
- 27 Dec 2016 Planned primary completion date changed from 1 May 2018 to 1 Jun 2018.
- 08 Nov 2016 New trial record